Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2023
Referred to the Subcommittee on Health.
Mar 3, 2023
Referred to the House Committee on Energy and Commerce.
Mar 3, 2023
Introduced in House
Plain-English summary
Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act
This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2